Sign up to save your podcasts
Or
Share Abi Vijenthira, MD, and Anca Prica, MD, on Why Certain DLBCL Therapies May Not Be Cost Effective
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Abi Vijenthira, MD, and Anca Prica, MD, on Why Certain DLBCL Therapies May Not Be Cost Effective
Drs. Vijenthira and Prica, both of the Princess Margaret Cancer Centre, speak with host Chadi Nabhan, MD, MBA, FACP, about their analysis on the cost-effectiveness of pola-R-CHP and second-line CAR-T in patients with DLBCL, and why its results differed from a similar study published in the journal Blood in December 2022.
View all episodes
By Rahul Banerjee, MD
4.8
2727 ratings
Drs. Vijenthira and Prica, both of the Princess Margaret Cancer Centre, speak with host Chadi Nabhan, MD, MBA, FACP, about their analysis on the cost-effectiveness of pola-R-CHP and second-line CAR-T in patients with DLBCL, and why its results differed from a similar study published in the journal Blood in December 2022.
More shows like The HemOnc Pulse
View all
JAMA Editors' Summary
137 Listeners
NEJM This Week
323 Listeners
JAMA Clinical Reviews
499 Listeners
Hematologic Oncology Update
76 Listeners
Research To Practice | Oncology Videos
121 Listeners
The Hematologist
28 Listeners
Core IM | Internal Medicine Podcast
1,146 Listeners
OncoPharm
187 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
368 Listeners
Blood Podcast
52 Listeners
Healthcare Unfiltered
138 Listeners
Blood Cancer Talks
48 Listeners
Two Onc Docs
193 Listeners
WolverHeme Happy Hour
31 Listeners